We are live on
!
Find out more
ECM
Endurant Capital Management Portfolio holdings
AUM
$17.4M
1-Year Est. Return
7.38%
This Fund
S&P 500
This Quarter
Est. Return
+13.07%
1 Year Est. Return
+7.38%
3 Year Est. Return
+18.38%
5 Year Est. Return
+100.61%
10 Year Est. Return
–
AUM
$246M
AUM Growth
-$60.8M
(-20%)
Cap. Flow
-$70.1M
Cap. Flow
% of AUM
-28.47%
Top 10 Holdings %
Top 10 Hldgs %
67.39%
Holding
78
New
29
Increased
8
Reduced
16
Closed
23
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Centene
CNC
|
+$13.8M |
| 2 |
Merck
MRK
|
+$12.9M |
| 3 |
Sabra Healthcare REIT
SBRA
|
+$5.57M |
| 4 |
Cigna
CI
|
+$4.93M |
| 5 |
Elevance Health
ELV
|
+$4.91M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Humana
HUM
|
+$15.9M |
| 2 |
Takeda Pharmaceutical
TAK
|
+$14.3M |
| 3 |
Baxter International
BAX
|
+$12.6M |
| 4 |
Eli Lilly
LLY
|
+$12.4M |
| 5 |
Qiagen
QGEN
|
+$12.2M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 73.98% |
| 2 | Real Estate | 2.81% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
CTLT
26
DELISTED
CATALENT, INC.
CTLT
| $1.59M | 0.64% |
35,265
-104,812
| -75% | -$5.7M |
|
|
SILK
27
DELISTED
Silk Road Medical, Inc. Common Stock
SILK
| $1.58M | 0.64% |
+29,967
| New | +$1.46M |
|
28
HCA Healthcare
HCA
$88.7B
| $1.58M | 0.64% |
+6,595
| New | +$1.48M |
|
29
Healthpeak Properties
DOC
$15B
| $1.49M | 0.61% |
+59,578
| New | +$1.45M |
|
|
TERN
30
DELISTED
Terns Pharmaceuticals
TERN
| $1.38M | 0.56% |
+135,994
| New | +$905K |
|
31
Charles River Laboratories
CRL
$12.6B
| $1.36M | 0.55% |
+6,258
| New | +$1.37M |
|
32
Arrowhead Research
ARWR
$12.3B
| $1.14M | 0.46% |
+28,187
| New | +$934K |
|
33
BioAtla
BCAB
$5.52M
| $1.13M | 0.46% |
+2,728
| New | +$1.13M |
|
34
10x Genomics
TXG
$6.08B
| $1.11M | 0.45% |
+30,357
| New | +$993K |
|
35
Alnylam Pharmaceuticals
ALNY
$30.6B
| $1.09M | 0.44% |
+4,596
| New | +$980K |
|
|
GRTS
36
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
| $976K | 0.4% |
+282,935
| New | +$808K |
|
37
Thermo Fisher Scientific
TMO
$214B
| $875K | 0.36% |
+1,589
| New | +$842K |
|
38
Axsome Therapeutics
AXSM
$11B
| $869K | 0.35% |
+11,264
| New | +$673K |
|
39
Dentsply Sirona
XRAY
$2.86B
| $703K | 0.29% |
+22,088
| New | +$666K |
|
40
PTC Therapeutics
PTCT
$5.78B
| $683K | 0.28% |
+17,886
| New | +$744K |
|
41
Intellia Therapeutics
NTLA
$1.53B
| $572K | 0.23% |
+16,401
| New | +$780K |
|
|
42
Baxter International
BAX
$14.1B
| $561K | 0.23% |
11,008
-234,085
| -96% | -$12.6M |
|
|
IGMS
43
DELISTED
IGM Biosciences
IGMS
| $516K | 0.21% |
+30,320
| New | +$606K |
|
44
Actinium Pharmaceuticals
ATNM
$23.5M
| $486K | 0.2% |
+45,612
| New | +$463K |
|
|
ETNB
45
DELISTED
89bio
ETNB
| $468K | 0.19% |
+36,784
| New | +$331K |
|
46
Iovance Biotherapeutics
IOVA
$1.94B
| $451K | 0.18% |
+70,655
| New | +$552K |
|
|
ITOS
47
DELISTED
iTeos Therapeutics
ITOS
| $411K | 0.17% |
+21,041
| New | +$411K |
|
|
INBX
48
DELISTED
Inhibrx, Inc. Common Stock
INBX
| $332K | 0.13% |
+13,485
| New | +$396K |
|
49
Maravai LifeSciences
MRVI
$948M
| $307K | 0.12% |
21,458
-1,251
| -6% | -$19.7K |
|
50
Biodesix
BDSX
$236M
| $286K | 0.12% |
6,222
-285
| -4% | -$7.75K |
|
Similar funds
VAFP
CA
SCM
FWM
TOPU
CCMU
TGI
HSCU
Endurant Capital Management's Q4 2022 Portfolio in Review
As of Q4 2022, Endurant Capital Management held 78 positions worth $246M, down 20% from $307M the previous quarter. Its ten largest holdings account for 67% of the portfolio.
Endurant Capital Management withdrew a net $70.1M in Q4 2022, closing 23 positions and reducing 16 holdings. Its most notable exit was Humana, an estimated $15.9M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 74% of assets, down from 77% a quarter earlier, followed by Real Estate.
Against the trend, Endurant Capital Management opened a new position in Centene worth $13.8M.
- Endurant Capital Management's largest Q4 2022 buy was Centene: 168,363 shares worth $13.8M.
- Endurant Capital Management added most to Cigna in Q4 2022, an estimated $4.93M increase.
- Endurant Capital Management's biggest Q4 2022 reduction was Baxter International, cutting an estimated $12.6M.
- Endurant Capital Management fully exited Humana in Q4 2022, selling an estimated $15.9M.
- Endurant Capital Management's ten largest holdings make up 67% of its $246M portfolio in Q4 2022.
- Endurant Capital Management opened 29 new positions and closed 23 in Q4 2022.
- Endurant Capital Management's portfolio value fell 20% quarter-over-quarter to $246M.
Based on Endurant Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.